annb0t
Top 20
Design Therapeutics, Inc.
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxiato Be Initiated Soon
Topline Data from Phase 1 Trial Expected in the Second Half of 2022
CARLSBAD, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that its Investigational New Drug Application (IND) for its lead candidate, DT-216, for the treatment of Friedreich ataxia (FA), was...
>>> Read more: Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC⢠Molecule for Friedreich Ataxia
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxiato Be Initiated Soon
Topline Data from Phase 1 Trial Expected in the Second Half of 2022
CARLSBAD, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that its Investigational New Drug Application (IND) for its lead candidate, DT-216, for the treatment of Friedreich ataxia (FA), was...
>>> Read more: Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC⢠Molecule for Friedreich Ataxia
